Literature DB >> 12093300

Standardisation of costs: the Dutch Manual for Costing in economic evaluations.

Jan B Oostenbrink1, Marc A Koopmanschap, Frans F H Rutten.   

Abstract

The lack of a uniform costing methodology is often considered a weakness of economic evaluations that hinders the interpretation and comparison of studies. Standardisation is therefore an important topic within the methodology of economic evaluations and in national guidelines that formulate the formal requirements for studies to be considered when deciding on the reimbursement of new medical therapies. Recently, the Dutch Manual for Costing: Methods and Standard Costs for Economic Evaluations in Health Care (further referred to as "the manual") has been published, in addition to the Dutch guidelines for pharmacoeconomic research. The objectives of this article are to describe the main content of the manual and to discuss some key issues of the manual in relation to the standardisation of costs. The manual introduces a six-step procedure for costing. These steps concern: the scope of the study;the choice of cost categories;the identification of units;the measurement of resource use;the monetary valuation of units; andthe calculation of unit costs. Each step consists of a number of choices and these together define the approach taken. In addition to a description of the costing process, five key issues regarding the standardisation of costs are distinguished. These are the use of basic principles, methods for measurement and valuation, standard costs (average prices of healthcare services), standard values (values that can be used within unit cost calculations), and the reporting of outcomes. The use of the basic principles, standard values and minimal requirements for reporting outcomes, as defined in the manual, are obligatory in studies that support submissions to acquire reimbursement for new pharmaceuticals. Whether to use standard costs, and the choice of a particular method to measure or value costs, is left mainly to the investigator, depending on the specific study setting. In conclusion, several instruments are available to increase standardisation in costing methodology among studies. These instruments have to be used in such a way that a balance is found between standardisation and the specific setting in which a study is performed. The way in which the Dutch manual tries to reach this balance can serve as an illustration for other countries.

Entities:  

Mesh:

Year:  2002        PMID: 12093300     DOI: 10.2165/00019053-200220070-00002

Source DB:  PubMed          Journal:  Pharmacoeconomics        ISSN: 1170-7690            Impact factor:   4.981


  19 in total

Review 1.  Standard cost lists for healthcare in Canada. Issues in validity and inter-provincial consolidation.

Authors:  P Jacobs; N P Roos
Journal:  Pharmacoeconomics       Date:  1999-06       Impact factor: 4.981

Review 2.  Guidelines for pharmacoeconomic studies. Recommendations from the panel on cost effectiveness in health and medicine. Panel on cost Effectiveness in Health and Medicine.

Authors:  J E Siegel; G W Torrance; L B Russell; B R Luce; M C Weinstein; M R Gold
Journal:  Pharmacoeconomics       Date:  1997-02       Impact factor: 4.981

3.  The November 1995 revised Australian guidelines for the economic evaluation of pharmaceuticals.

Authors:  P C Langley
Journal:  Pharmacoeconomics       Date:  1996-04       Impact factor: 4.981

4.  The friction cost method for measuring indirect costs of disease.

Authors:  M A Koopmanschap; F F Rutten; B M van Ineveld; L van Roijen
Journal:  J Health Econ       Date:  1995-06       Impact factor: 3.883

Review 5.  A comparative review of pharmacoeconomic guidelines.

Authors:  P Jacobs; J Bachynsky; J F Baladi
Journal:  Pharmacoeconomics       Date:  1995-09       Impact factor: 4.981

6.  Towards a new approach for estimating indirect costs of disease.

Authors:  M A Koopmanschap; B M van Ineveld
Journal:  Soc Sci Med       Date:  1992-05       Impact factor: 4.634

7.  Standardization of the economic evaluation of health technologies. European developments.

Authors:  J Rovira
Journal:  Med Care       Date:  1996-12       Impact factor: 2.983

8.  Pharmacoeconomics: evaluating the evaluators.

Authors:  A Haycox; T Walley
Journal:  Br J Clin Pharmacol       Date:  1997-05       Impact factor: 4.335

9.  Hospital selection for unit cost estimates in multicentre economic evaluations. Does the choice of hospitals make a difference?

Authors:  R Goeree; A Gafni; M Hannah; T Myhr; G Blackhouse
Journal:  Pharmacoeconomics       Date:  1999-06       Impact factor: 4.981

10.  Patient and informal caregiver time in cost-effectiveness analysis. A response to the recommendations of the Washington Panel.

Authors:  W B Brouwer; M A Koopmanschap; F F Rutten
Journal:  Int J Technol Assess Health Care       Date:  1998       Impact factor: 2.188

View more
  133 in total

1.  Two-tier charging in Maputo Central Hospital: costs, revenues and effects on equity of access to hospital services.

Authors:  Barbara McPake; Charles Hongoro; Giuliano Russo
Journal:  BMC Health Serv Res       Date:  2011-06-02       Impact factor: 2.655

2.  Effectiveness of classroom based crew resource management training in the intensive care unit: study design of a controlled trial.

Authors:  Peter F Kemper; Martine de Bruijne; Cathy van Dyck; Cordula Wagner
Journal:  BMC Health Serv Res       Date:  2011-11-10       Impact factor: 2.655

3.  The analysis of multinational cost-effectiveness data for reimbursement decisions: a critical appraisal of recent methodological developments.

Authors:  Andrea Manca; Mark J Sculpher; Ron Goeree
Journal:  Pharmacoeconomics       Date:  2010       Impact factor: 4.981

4.  Providing systematic guidance in pharmacoeconomic guidelines for analysing costs.

Authors:  Philip Jacobs; Arto Ohinmaa; Bruce Brady
Journal:  Pharmacoeconomics       Date:  2005       Impact factor: 4.981

Review 5.  Penny and pound wise: pharmacoeconomics from a governmental perspective.

Authors:  Mike F van Oostenbruggen; Ronald B Jansen; Katja Mur; Huib Kooijman
Journal:  Pharmacoeconomics       Date:  2005       Impact factor: 4.981

Review 6.  International variation in resource utilisation and treatment costs for rheumatoid arthritis: a systematic literature review.

Authors:  Hubertus Rosery; Rito Bergemann; Stefanie Maxion-Bergemann
Journal:  Pharmacoeconomics       Date:  2005       Impact factor: 4.981

Review 7.  Economic evaluations: a new avenue of outcome assessment in spinal disorders.

Authors:  Nicole van der Roer; Norbert Boos; Maurits W van Tulder
Journal:  Eur Spine J       Date:  2005-12-01       Impact factor: 3.134

Review 8.  Health economic evaluation in lumbar spinal fusion: a systematic literature review anno 2005.

Authors:  Rikke Soegaard; Finn B Christensen
Journal:  Eur Spine J       Date:  2005-12-21       Impact factor: 3.134

Review 9.  Introducing economic evaluation as a policy tool in Korea: will decision makers get quality information? : a critical review of published Korean economic evaluations.

Authors:  Kun-Sei Lee; Werner B F Brouwer; Sang-Il Lee; Hye-Won Koo
Journal:  Pharmacoeconomics       Date:  2005       Impact factor: 4.981

10.  The cost effectiveness of behavioural graded activity in patients with osteoarthritis of hip and/or knee.

Authors:  Veerle M H Coupé; Cindy Veenhof; Maurits W van Tulder; Joost Dekker; Johannes W J Bijlsma; Cornelia H M Van den Ende
Journal:  Ann Rheum Dis       Date:  2006-07-31       Impact factor: 19.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.